https://en.wikipedia.org/wiki/Cytotoxic_T-lymphocyte_associated_protein_4 QT:{{” Cytotoxic T-lymphocyte associated protein 4, (CTLA-4) also known as CD152 (cluster of differentiation 152), is a protein receptor that functions as an immune checkpoint and downregulates immune responses. “}}
Posts Tagged ‘breakthrough0mg’
Cytotoxic T-lymphocyte associated protein 4 – Wikipedia
February 19, 2026PD-1 and PD-L1 inhibitors – Wikipedia
February 19, 2026PD-1 and PD-L1 inhibitors – Wikipedia
February 15, 2026How Immunotherapy Extended President Jimmy Carter’s Life – Cancer Research Institute
February 15, 2026https://www.cancerresearch.org/blog/how-immunotherapy-extended-president-jimmy-carters-life QT:{{”
Leading up to its FDA approval, Keytruda® proved very effective in combating advanced melanoma. Following four rounds of Keytruda® treatment in tandem with radiation therapy, his doctors declared that President Carter no longer had metastasized melanoma.
“}}
The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer) – PMC
February 15, 2026https://pmc.ncbi.nlm.nih.gov/articles/PMC6231274/
QT:{{
Allison studied the T-cell protein CTLA-4 in the 1990s. He and other teams of scientists had made the observation that CTLA-4 functions as a brake on T cell activities. He had developed an antibody that could block CTLA-4 function. ….
Honjo discovered PD-1 expressed on the surface of T-cells in 1992 [5]. It took many years of work to unravel its role in immune response. The results showed that PD-1 operates by a different mechanism from CTLA-4. In preclinical studies, Honjo and others showed that PD-1 blockade was a promising strategy in the fight against cancer [6, 7]. “}}
linkstream2 microblog 